OROS oxybutynin

Phase 3Small molecule

Johnson & Johnson

OROS oxybutynin is one of 184 small molecule programs targeting Low back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

183

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Attention Deficit Hyperactivity DisorderActive, not recruiting

Cancer PainActive, not recruiting

Chronic PainActive, not recruiting

Urinary IncontinenceActive, not recruiting

OsteoarthritisActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Attention Deficit Hyperactivity DisorderPhase 3

Active, not recruiting

Cancer PainPhase 3

Active, not recruiting

Chronic PainPhase 1

Active, not recruiting

Urinary IncontinencePhase 3

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

OROS oxybutynin

Johnson & Johnson

Phase 3

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Toradol

Roche

Preclinical

1 5

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 6

Cataflam

Bayer Aspirin

Glucophage

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder4 trials

A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00269789

An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01060150·115 enrolled

A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00269802

Show 1 more trial

An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00269776

Cancer Pain3 trials

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00411034·463 enrolled

A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00410540·202 enrolled

Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00410787·68 enrolled

Urinary incontinence2 trials

A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00269724·250 enrolled

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00269750·100 enrolled

Chronic pain2 trials

Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00410943·169 enrolled

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Completed·AAlza Corporation, DE, USA·Phase 1·NCT00410878·22 enrolled

Double-blind1 trial

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

Completed·MMassachusetts General Hospital·Phase 4·NCT00302354·50 enrolled

6 more indications

Quality of Life1 trial

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00399048·140 enrolled

Chronic1 trial

A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00410644·463 enrolled

Osteoarthritis1 trial

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00411164·990 enrolled

Low back pain1 trial

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00411268·207 enrolled

Moderate to Severe Postoperative Pain1 trial

A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

Completed·AAlza Corporation, DE, USA·Phase 2·NCT00411307·50 enrolled

Unspecified1 trial

Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)

Completed·AAlza Corporation, DE, USA·Phase 3·NCT00410748·388 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for OROS oxybutynin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OROS oxybutynin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OROS oxybutynin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

OROS oxybutynin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder4 trials

Cancer Pain3 trials

Urinary incontinence2 trials

Chronic pain2 trials

Double-blind1 trial

Quality of Life1 trial

Chronic1 trial

Osteoarthritis1 trial

Low back pain1 trial

Moderate to Severe Postoperative Pain1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News